You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 21, 2024

OMONTYS PRESERVATIVE FREE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Omontys Preservative Free, and when can generic versions of Omontys Preservative Free launch?

Omontys Preservative Free is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are six patents protecting this drug.

This drug has one hundred and fourteen patent family members in thirty-four countries.

The generic ingredient in OMONTYS PRESERVATIVE FREE is peginesatide acetate. Additional details are available on the peginesatide acetate profile page.

DrugPatentWatch® Generic Entry Outlook for Omontys Preservative Free

Omontys Preservative Free was eligible for patent challenges on March 27, 2016.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

Summary for OMONTYS PRESERVATIVE FREE
International Patents:114
US Patents:6
Applicants:1
NDAs:1
Formulation / Manufacturing:see details
DailyMed Link:OMONTYS PRESERVATIVE FREE at DailyMed
Drug patent expirations by year for OMONTYS PRESERVATIVE FREE
Anatomical Therapeutic Chemical (ATC) Classes for OMONTYS PRESERVATIVE FREE

US Patents and Regulatory Information for OMONTYS PRESERVATIVE FREE

OMONTYS PRESERVATIVE FREE is protected by six US patents.

Patents protecting OMONTYS PRESERVATIVE FREE

Peptides that bind to the erythropoietin receptor
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE

Peptides that bind to the erythropoietin receptor
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE

Peptides that bind to the erythropoietin receptor
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Erythropoietin receptor peptide formulations and uses
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE

Spacer moiety for poly (ethylene glycol) modified peptide based compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Erythropoietin receptor peptide formulations and uses
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-006 Mar 27, 2012 DISCN No No ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-005 Mar 27, 2012 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-006 Mar 27, 2012 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for OMONTYS PRESERVATIVE FREE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-001 Mar 27, 2012 ⤷  Sign Up ⤷  Sign Up
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-005 Mar 27, 2012 ⤷  Sign Up ⤷  Sign Up
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-006 Mar 27, 2012 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for OMONTYS PRESERVATIVE FREE

See the table below for patents covering OMONTYS PRESERVATIVE FREE around the world.

Country Patent Number Title Estimated Expiration
Israel 171782 PEPTIDE DIMERS WHICH COMPRISE POLYETHYLENE GLYCOL THAT BIND TO THE ERYTHROPOIETIN RECEPTOR, PHARMACEUTICAL COMPOSITIONS THEREOF AND USE THEREOF ⤷  Sign Up
Iceland 8167 Peptíð sem bindast rauðkornavakaviðtakanum ⤷  Sign Up
Iceland 8168 Rýmishelft fyrir fjöl(etýlenglýkól) breytt peptíð ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.